Goldman Sachs Group Inc. reissued their buy rating on shares of Shire PLC (LON:SHP) in a report published on Wednesday. The firm currently has a GBX 6,300 ($77.97) price target on the biopharmaceutical company’s stock.

A number of other analysts have also commented on SHP. Royal Bank Of Canada reaffirmed an outperform rating on shares of Shire PLC in a research note on Wednesday, June 15th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 6,300 ($77.97) price objective (up previously from GBX 5,600 ($69.31)) on shares of Shire PLC in a research report on Monday, August 1st. Jefferies Group raised their price objective on Shire PLC from GBX 6,050 ($74.88) to GBX 6,600 ($81.68) and gave the company a buy rating in a research report on Wednesday, August 3rd. Shore Capital reissued a buy rating on shares of Shire PLC in a research report on Tuesday, June 14th. Finally, Deutsche Bank AG reissued a buy rating and set a GBX 6,000 ($74.26) price objective on shares of Shire PLC in a research report on Monday, September 19th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have given a buy rating to the stock. Shire PLC has a consensus rating of Buy and an average price target of GBX 5,841.33 ($72.29).

Analyst Recommendations for Shire PLC (LON:SHP)

Shire PLC (LON:SHP) opened at 5087.00 on Wednesday. The company’s 50-day moving average is GBX 4,998.05 and its 200 day moving average is GBX 4,592.96. The company’s market cap is GBX 34.73 billion. Shire PLC has a 52-week low of GBX 2,707.19 and a 52-week high of GBX 5,377.00.

The firm also recently declared a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were issued a GBX 3.51 ($0.04) dividend. The ex-dividend date was Thursday, September 8th. This represents a yield of 0.07%.

In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the stock in a transaction that occurred on Friday, September 30th. The shares were bought at an average cost of GBX 5,010 ($62.00) per share, with a total value of £6,663.30 ($8,246.66).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.